Impact: Ang-2 ability to predict OS at diagnosis could be of interest in the selection of patients eligible to intermittent or sequential therapeutic strategies dedicated to the optimization of patient's quality of life and chemotherapy cost-effectiveness. Several investigations were performed to determine the role of cancer-related angiogenesis in mCRC prognosis. Over the last decade, many seric potential prognostic factors were investigated in mCRC patients without any positive association with OS at baseline. (9) (10) The presence of alternative angiogenesis pathways promoting cancer progression was firstly suggested by the lack of efficacy of VEGF blockade in some tumor models in mice. (11) Further studies demonstrated that Angiopoietin-2 (Ang-2), a ligand of Tie2 receptor (12) was able to induce an anarchical blood vessel organization during cancer progression. (13) (14) Preclinical studies confirmed that VEGFR and Tie2 signalling were two independent mechanisms promoting tumor angiogenesis and cancer progression. (15) Moreover, VEGF and Ang-2 were independent biomarkers at baseline to predict survival in advanced hepatocarcinoma patients treated by sorafenib in the SHARP study. (16) In first-line mCRC, Goede V. and colleagues proposed Ang-2 as a possible prognostic biomarker for OS at diagnosis, based on a pioneering study performed in 34 patients treated with bevacizumab and chemotherapy. (17) In a cohort of 51 mCRC patients treated by FOLFIRI-3 and bevacizumab we have also recently observed an association between baseline Ang-2 plasmatic levels, OS and PFS. (18) Other exploratory studies pointed out its potential prognostic value by the description of an association between Ang-2 and OS or PFS, in small cohorts of patients. (19) (20) However, the independent and additional Ang-2 prognostic value for OS, among the Consequently, we decided to perform a validation study to assess the prognostic value of Ang-2 in mCRC. For this purpose, Ang-2 plasmatic levels were monitored in 177 mCRC patients enrolled in two prospective clinical trials, to confirm the potential prognostic value of Ang-2 as a biomarker of interest for the prediction of OS. We also investigate the added value of Ang-2 at baseline among conventional parameters.
INTRODUCTION

MATERIALS AND METHODS
Population
Individual patient data were collected from two previous prospective cohorts, both containing bevacizumab treatment in first-line mCRC patients.
The "cohort set-1", was a pilot, single-arm, multicenter, phase II trial conducted to characterize the response rate and toxicity profile of a FOLFIRI- In both studies all patients gave written informed consent, and were followed until death.Data were anonymized. Population selection during the study is summarized in the flow chart (Figure 1 ).
Data extraction:
The following data were collected for each patient in the two cohorts: center and Ang-2 plasma sample measurement procedure is precisely described in supplementary materials (Supp methods).
Statistical analysis
We provided the mean (SD) values and frequency (percentages) for the description of continuous and categorical variables, respectively. The means and the proportion were compared using Student's t test and the chi-squared test (or Fisher's exact test, if appropriate), respectively. Due to the skewed Angiopoietin-2 distribution we used for its description the median, and the interquartile range for the dispersion measurement, as recommended. (26) Wilcoxon rank-sum test was performed for Ang-2 distribution comparison among the cohort set.
OS was calculated from the date of study enrolment to the date of death from any cause. Alive patients were censored at the last follow-up. OS was estimated using Kaplan Meier method and described using median or rate at specific time points with 95%CI. Follow-up was calculated using reverse Kaplan-Meier estimation. (27) A Cox proportional hazard model was performed to estimate the hazard ratio (HR) and 95% confidence intervals for the factors associated with OS.
The association of parameters at enrolment with OS was first assessed using univariate Cox analysis and then included (for those with p<0.05) in a final multivariate Cox regression model with stepwise backward elimination. When used in continuous in the Cox modelisation, Ang-2 variable had to be normalized by logarithmic transformation, considering its skewed distribution. Hazard proportionality was checked by plotting log-minus-log survival curves.
Accuracy of the model was checked regarding two parameters: discrimination and calibration. (28) The predictive value and the discrimination ability of the model was evaluated with Harrell's Concordance (C)-index. One thousand random samples of the population were used to derive 95%CI for the Harrell's Concordance statistic.
Calibration and goodness of fit of the model were assessed by using the extension of Hosmer-Lemeshow test for survival analysis and p-value greater than 0.1 was considered as an indicator for acceptable agreement.
Internal validity of the model was assessed by a bootstrap sample procedure.
Several approaches have been proposed to assess the performance in samples of the same population (internal validation). (29) Sensitivity analyses were performed for univariate and multivariate Cox models with a stratified approach on the cohort set parameter that allowed to consider the two cohort heterogeneities in the Cox modelisation.
We further focused on the improvement of one reference prognostic model for OS (GERCOR model) performance after the inclusion of Ang-2 measurement, comparing two sets of predictions for death: one based on a Cox proportional hazard model without Ang-2 parameter and one based on a model with Ang-2 parameter.
The discrimination ability and incremental value of Ang-2 level to the GERCOR score was evaluated with the use of C statistic. This analysis was repeated 1,000 times using bootstrap samples to derive 95%CIs for the difference in the C statistic between models. We also used net continuous reclassification improvement (NRI) and integrated discrimination improvement (IDI) to quantify the performance and the net benefit of the addition of Ang-2 to the reference model for the prediction of 48 months death probability. The analyses were conducted using SAS 9.2 (Statistical Analysis System, Cary, NC, USA) and R 3.0.2 (R foundation for Statistical Computing). All statistical tests were 2-sided, and probability values <0.05 were regarded as significant.
RESULTS
Population:
The characteristics of the 177 eligible patients are summarized in table 1. Fifty-one samples were available from "cohort set-1", and 126 from "cohort set-2". Patient's characteristics of these two cohorts are similar, except for sex and liver metastatic involvement. Ang-2 values were also different in the two cohorts. Of note, the statistical unbalance in metastatic sites between the two cohorts was awaited since liver metastasis was an inclusion criteria in the "cohort set-2". The rate of PS 2 was 2% in the "cohort set-1", instead of 5% in the "cohort set-2", we consequently differentiated the patients PS 0 from the patients PS > 0. There were 23 (45%), and 45 (36%) patients with liver exclusive metastatic sites. Surgery of the primary tumor was performed in 28 (57%) and 82 (65%) patients, in the cohorts set-1 and set-2, respectively. LDH values at baseline were available in 33 and 82 patients and increased upper limit normal values in 13 (39%) and 46 (56%) patients of cohort set-1 and set-2, respectively. 
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Final Multivariate model performance assessment
Accuracy of the model was checked regarding two parameters: discrimination and calibration, which measure the ability to separate patients with different prognosis and to provide unbiased survival predictions in groups of similar patients, respectively.
Our final multivariable Cox model exhibited good calibration (HosmerLemeshow with deciles p=0.8) and acceptable discrimination (C-statistic 0.64; 95%CI: 0.58-0.68).
Internal validation of the final model
With the replicated datasets (n=1000) derived from the bootstrap sample procedure, uncertainties around hazard ratio estimates can be measured.
Bootstrapping results for the internal validation reflect the robustness of the final model (HR 95%CI percentile for LDH: 1.039 to 2.628 and HR 95%CI percentile for Ang-2 (log value): 1.161 to 2.263).
Sensitivity analysis
Considering the differences observed between the two cohorts ( 
Proposal for an implementation of Ang-2 monitoring in clinical practice
After the statistical investigation and determination of the baseline Ang-2 added value for predicting OS among the conventional factors, we investigated the possibility to provide a simple implementation of Ang-2 monitoring in clinical practice.
Cut-off value of Ang-2 fixed at 5 ng/mL
Simple implementation of Ang-2 monitoring in clinical practice is first guided by the determination for a relevant cut-off in order to categorize patients into groups with low and high Ang-2 level at baseline.
A preliminary set of experiments was done by dosing the Ang-2 value in 41 healthy volunteers, blood donors in the Etablissement Français du Sang (EFS, Bourgogne Franche-Comté). These volunteers were major (more than 55 years old), having signed an informed consent and were randomly chosen. We hypothesized that this population have no active angiogenesis. Among these healthy donors, 40
(98%) had mean values lower than 5 ng/mL. This observation was in agreement with the results previously published by Goede et al where levels of Ang-2 were inferior to 5 ng/mL in the 33 healthy volunteers.
In our study population, the median value of Ang-2 was 4.045 ng/mL for the 109 patients included in the final analysis. Of note, similar results were observed when the median value was used as a cut-off. A value of 5 ng/mL was then chosen considering results provided by previous publications (17, 20) regarding that 98% of healthy volunteers have baseline plasmatic levels of Ang-2 below 5ng/mL. In consequence, in order to investigate a cut-off value for clinical use, a level of 5 ng/mL seemed to be a relevant choice (Figure 2) .
Phenotypic characterisation of patients with high and low Ang-2 levels
The determination of 5 ng/mL as a cut-off value allowed us to classify patients into two groups: low (<5 ng/mL) and high (>=5 ng/mL) Ang-2 level group at baseline. As expected, we noted a significant difference for the GERCOR prognostic score distribution among groups of patients with low and high Ang-2 levels (42%-38%-20% vs 7%-48%-45%; p=0.0002 for low, intermediate and high risk GERCOR group, respectively).
Kaplan-Meier curves for OS by combining Ang-2 binary information and conventional score
Considering the added value of Ang-2 measurement for OS risk stratification among conventional factors, previously described, we investigated the interest for a combination of Ang-2 simple binary information and GERCOR prognostic score in clinical practice. figure 3, panel B) .
Finally, the Ang-2 binary status was combined with the GERCOR score. In low and high-risk patients, the Ang-2 value only triggers a trend in better discrimination of prognosis, without statistical significance (p=0.27 and 0.45, respectively). However, in the intermediate risk GERCOR group (n=45, 41%), the consideration of Ang-2 binary status allowed us to split the population in two subsets of patients. Indeed, patients with low Ang-2 level had a significant better prognosis than those with high Interestingly, patients with intermediate risk and Ang-2< 5 ng/mL (n=26, 58%) had a similar risk profile than the GERCOR low risk patients (OS=26.3 and 27.1 months, respectively). Similarly, those with Ang-2> 5 ng/mL (n=19, 42%) had a similar risk profile than the GERCOR high-risk patients (OS=17.6 and 19.7 months, respectively, figure 3 , panel D).
DISCUSSION:
The present results, consistently with previous studies, confirm that Angiopoietin-2 is a biomarker of interest for OS prediction in non-previously treated mCRC patients. (17) (18) The main interest of Ang-2 as a biomarker is its ability to predict OS when measured at diagnosis, before treatment initiation. Low levels of Ang-2 identify a significant population (n=69; 63%) displaying an encouraging median OS of 26. In conclusion, the assessment of the Ang-2 value at baseline could guide clinicians in stratifying risk for death in first-line mCRC patients and in providing a basis for early and adapted therapeutic interventions. The determination of Ang-2 at baseline should allow death risk stratification that could also be useful in the design optimization for future clinical trials. Population selection during the study is summarized in the flow chart.
In the left panel the population selection during the study is described.
In the right panel the derived analysis and their synthetic results are summarized. In our study population, the median value of Ang-2 was 4.045 ng/mL for the 109 patients included in the final analysis. In consequence, in order to investigate a cutoff value for clinical use, a level of 5 ng/mL seemed to be a relevant choice. GERCOR's group (n=45) reclassified these patients in two groups with similar profiles than low and high risk GERCOR's groups.
